Quantcast
Last updated on April 24, 2014 at 5:50 EDT

Patent Protection Granted For The Elimination of Anthrax

January 29, 2014

The ability to remediate buildings following a weaponized biological attack may have been achieved with AsepticSure®


SAN FRANCISCO, Jan. 29, 2014 /PRNewswire/ — Medizone International, Inc. (The Company) (MZEI:OB, MZEI:QB) has just been granted its fourth patent for its revolutionary enclosed space room disinfection system, AsepticSure. The United States Patent and Trademark Office has issued US Patent number 8,636,951 titled BIO-TERRORISM COUNTERACTION USING OZONE AND HYDROGEN PEROXIDE.

Following on the heels of patent protection being established for its health care related patent applications, the Company has now been awarded a patent for its government variant of AsepticSure intended for use by defense agencies as a response to a biological attack on critical buildings, infrastructure and resources.

Dr. Michael E. Shannon, Medizone International’s President explained, “At our Innovation Park, Queens University laboratories, we have been successful in completely eliminating Bacillus atropheus and Bacillus subtilis, both internationally recognized study surrogates for Anthrax, one of the most difficult weaponized pathogens to kill. Being able to eliminate these surrogates for Anthrax with our technology almost assures we now have the ability to remediate critical public infrastructure following a biological attack and restore it to service without damaging important and expensive equipment including communications systems. Militaries have struggled with this problem for decades and, until now, this simply has not been possible.”

“To now have patent protection granted for this system,” stated Edwin Marshall, Medizone’s CEO, “should allow the Company protected access to a potentially lucrative government market due to the unique capability of AsepticSure’s government variant.”

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

For Medizone International Inc. Investor inquiries, please contact:

John Pentony, Investor Relations
T: (415) 331-0202
E: j.pentony@medizoneint.com

For Medizone International Inc. Media inquiries, please contact:

Gary Hanauer, Media Contact
T: (510) 686-1238
E: GarHan@aol.com

For more information, visit:
http://www.medizoneint.com
Email: operations@medizoneint.com

SOURCE Medizone International, Inc.


Source: PR Newswire